Biotech Mergers and Acquisitions are Here to Stay; Here's How to Play
It's difficult for the average market participant to assess biotech companies to build a position in any one stock. It is much easier to understand the economic imperative of large pharmas and biotechs to acquire smaller biotech companies to get their drug pipeline. Sometimes large pharma companies even go out and buy really big biotechs, for e.g. Bristol-Myers (BMY) spending tens of billions of dollars to buy Celgene (CELG). It was mostly about CELG's internal drug pipeline and its own investment in small